Notably, pharmacological inhibition of CBP/p300 as a therapeutic strategy in ER+ BC remains largely unexplored, despite clear evidence that CBP/p300 serve as critical ER co-activators [20,21,22,23,24,52]. This evidence concerns the gene EP300 and breast cancer.